Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Table 2

Pooled risk ratios of the selected trials.

Study	RR	95% CI	value
Overall survival	0.90	0.81–1.00	0.054
Progression-free survival	0.96	0.93–0.99	0.002
Objective response rate	1.04	0.94–1.16	0.452
Disease control rate	0.98	0.93–1.02	0.316
Any grade adverse events	1.03	0.98–1.08	0.202
Grade 3 ≥ adverse events	0.97	0.89–1.05	0.427

RR indicates risk ratio; 95% CI indicates 95% confidence interval.